Arch Venture Corp

Latest statistics and disclosures from ARCH Venture Management's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are MAZE, RAPP, VIR, ERAS, BEAM, and represent 85.41% of ARCH Venture Management's stock portfolio.
  • Added to shares of these 2 stocks: Generate Biomedicines Ord (+$24M), LYEL (+$9.8M).
  • Started 1 new stock position in Generate Biomedicines Ord.
  • Reduced shares in these 2 stocks: ERAS (-$64M), TXG (-$11M).
  • ARCH Venture Management was a net seller of stock by $-41M.
  • ARCH Venture Management has $677M in assets under management (AUM), dropping by 3.90%.
  • Central Index Key (CIK): 0001274403

Tip: Access up to 7 years of quarterly data

Positions held by Arch Venture Corp consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for ARCH Venture Management

ARCH Venture Management holds 10 positions in its portfolio as reported in the March 2026 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Maze Therapeatics (MAZE) 18.2 $123M 4.1M 29.85
 View chart
Rapport Therapeutics (RAPP) 17.2 $117M 3.7M 31.29
 View chart
Vir Biotechnology (VIR) 17.1 $116M 13M 8.96
 View chart
Erasca (ERAS) 16.9 $115M -35% 7.1M 16.18
 View chart
Beam Therapeutics (BEAM) 16.0 $108M 4.5M 23.83
 View chart
Lyell Immunopharma Com New (LYEL) 9.6 $65M +17% 3.2M 20.06
 View chart
Generate Biomedicines Com Shs 3.6 $24M NEW 1.9M 12.50
 View chart
10x Genomics Cl A Com (TXG) 0.7 $4.6M -70% 218k 21.23
 View chart
Gossamer Bio (GOSS) 0.4 $2.6M 8.1M 0.33
 View chart
Q32 Bio (QTTB) 0.3 $2.1M 321k 6.42
 View chart

Past Filings by ARCH Venture Management

SEC 13F filings are viewable for ARCH Venture Management going back to 2018

View all past filings